Rapid immunoassay for the determination of glial fibrillary acidic protein (GFAP) in serum.

Background: This study was aimed to develop a sensitive and rapid assay for the determination of glial fibrillary acidic protein (GFAP) in serum and to evaluate the clinical applicability in serum samples from patients with acute stroke.

Methods: The two-site chemiluminometric immunoassay, intended to use in a near-patient setting with a single incubation step (20 min), was used to measure serum samples from healthy blood donors and from patients with brain injury and correlated to serum S100B levels.

Results: The GFAP assay covered a concentration range up to 18 microg/L with an analytical sensitivity of 0.